ES2181682T3 - Utilizacion de licopeno para reducir la actividad de las celulas, en particular celulas cancerosas y preparaciones farmaceuticas. - Google Patents

Utilizacion de licopeno para reducir la actividad de las celulas, en particular celulas cancerosas y preparaciones farmaceuticas.

Info

Publication number
ES2181682T3
ES2181682T3 ES93203295T ES93203295T ES2181682T3 ES 2181682 T3 ES2181682 T3 ES 2181682T3 ES 93203295 T ES93203295 T ES 93203295T ES 93203295 T ES93203295 T ES 93203295T ES 2181682 T3 ES2181682 T3 ES 2181682T3
Authority
ES
Spain
Prior art keywords
cells
activity
reduce
lichopen
pharmaceutical preparations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93203295T
Other languages
English (en)
Inventor
Joseph Levy
Yoav Sharoni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lycored Ltd
Original Assignee
Lycored Natural Products Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11064278&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2181682(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lycored Natural Products Industries Ltd filed Critical Lycored Natural Products Industries Ltd
Application granted granted Critical
Publication of ES2181682T3 publication Critical patent/ES2181682T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

UN METODO PARA REDUCIR LA ACTIVIDAD DE UNA CELULA QUE CONSISTE EN ADMINISTRAR A LA CELULA DE UN SUJETO QUE LO NECESITE, BIEN DIRECTAMENTE O SISTEMATICAMENTE, UNA CANTIDAD DE LICOPENO EFECTIVA PARA REDUCIR LA ACTIVIDAD DE LA CELULA. SE DESCRIBEN LAS COMPOSICIONES FARMACEUTICAS UTILIZADAS PARA INHIBIR EL CRECIMIENTO DE LAS CELULAS CANCERIGENAS, QUE COMPRENDEN COMO INGREDIENTE ACTIVO UNA CANTIDAD DE LICOPENO EFECTIVA COMO PARA INHIBIR EL CRECIMIENTO DE LAS CELULAS CANCERIGENAS.
ES93203295T 1992-11-30 1993-11-25 Utilizacion de licopeno para reducir la actividad de las celulas, en particular celulas cancerosas y preparaciones farmaceuticas. Expired - Lifetime ES2181682T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL10392092A IL103920A (en) 1992-11-30 1992-11-30 Pharmaceutical preparations for inhibiting the growth of cancer cells and use of lycopene for the preparation thereof

Publications (1)

Publication Number Publication Date
ES2181682T3 true ES2181682T3 (es) 2003-03-01

Family

ID=11064278

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93203295T Expired - Lifetime ES2181682T3 (es) 1992-11-30 1993-11-25 Utilizacion de licopeno para reducir la actividad de las celulas, en particular celulas cancerosas y preparaciones farmaceuticas.

Country Status (14)

Country Link
US (1) US5827900A (es)
EP (1) EP0600544B1 (es)
JP (1) JPH06227970A (es)
KR (1) KR100301682B1 (es)
CN (1) CN1142774C (es)
AT (1) ATE225168T1 (es)
AU (1) AU679467B2 (es)
CA (1) CA2109750A1 (es)
DE (1) DE69332350T2 (es)
DK (1) DK0600544T3 (es)
ES (1) ES2181682T3 (es)
IL (1) IL103920A (es)
MX (1) MX9307509A (es)
ZA (1) ZA938791B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262109B1 (en) 1995-12-22 2001-07-17 Henkel Corporation Methods of preventing and/or treating high serum levels of cholesterol and/or lipids
WO1996019217A1 (en) * 1994-12-22 1996-06-27 Henkel Corporation Pharmaceutical compositions comprising lycopene
JP2750281B2 (ja) * 1995-06-15 1998-05-13 睦憲 藤原 高コレステロール血症治療剤
IT1283143B1 (it) * 1996-07-12 1998-04-07 Indena Spa Metodo di estrazione del licopene ed estratti che lo contengono
US20060160702A1 (en) * 1998-02-23 2006-07-20 Etienne Soudant Compositions comprising anti-proliferative agents and use thereof
GB9808796D0 (en) 1998-04-24 1998-06-24 Rowett Research Services Limit Antithrombotic agents
GB9821671D0 (en) 1998-10-05 1998-12-02 Muhlbauer Roman C Plant extracts for the treatment of increased bone resorption
IL129442A0 (en) * 1999-04-14 2000-02-29 Lycored Natural Prod Ind Ltd Compounds useful in reducing the level of insulin like growth factor-1 (IGF-1) in blood
US6399115B2 (en) 1999-09-10 2002-06-04 Glenn Braswell Method and composition for the treatment of benign prostate hypertrophy (BPH) and prevention of prostate cancer
IL135335A (en) 2000-03-29 2013-12-31 Lycored Natural Prod Ind Ltd Use of Carotenoids in Preparing Pharmaceuticals to Prevent Adverse Effects from Hormones and Pharmaceuticals Containing Carotenoids
US6989161B2 (en) * 2000-06-12 2006-01-24 Access Business Group International Llc Phytonutrient nutritional supplement
IL146449A0 (en) * 2001-11-12 2002-07-25 Lycored Natural Prod Ind Ltd Method and pharmaceutical preparations for reducing the activity of cells
EP1314438A1 (en) * 2001-11-23 2003-05-28 Nutricia N.V. Anti-proliferative composition
US20040001898A1 (en) * 2002-06-26 2004-01-01 Armand Malnoe Compositions and methods for detoxification and cancer prevention
RU2008115148A (ru) * 2005-10-11 2009-11-20 Ликоред Лтд. (Il) Продукты окисления каротиноидов как химиопредупреждающие и химиотерапевтические агенты
US8569356B2 (en) * 2005-10-25 2013-10-29 University Of Florida Research Foundation, Inc. Cyclin dependent kinase inhibitors
TW200738227A (en) * 2006-04-03 2007-10-16 Panatoz Corp One kind of multi-carotenoids and its administration
US8221803B1 (en) 2007-06-25 2012-07-17 OncoNatural Solutions, Inc. Composition for prostate health
CN101961354A (zh) * 2010-10-21 2011-02-02 蒋科罡 一种配用蜂王浆治疗肿瘤的中药及制法
CN101978986A (zh) * 2010-10-21 2011-02-23 蒋科罡 一种治疗肿瘤的中药制剂及制法
CN102894421A (zh) * 2011-07-24 2013-01-30 江西食方食坊中药食品有限公司 一种预防前列腺疾病的番杞饮料及其制备方法
CN107049998A (zh) * 2016-09-20 2017-08-18 南华大学附属第二医院 番茄红素顺式异构体在制备卵巢癌治疗药物中的应用
IT201700005649A1 (it) * 2017-01-19 2018-07-19 Associazione Oncologica Milanese Amo La Vita Onlus Uso di derivati di carotenoidi per ridurre la tossicità ed aumentare l’efficacia di trattamenti antitumorali anti-egfr
CN109172552A (zh) * 2018-07-18 2019-01-11 浙江格蕾斯生物科技有限公司 男性前列腺癌植物防治药物及制取方法
KR102220400B1 (ko) * 2019-03-06 2021-02-26 파이룽 머시너리 밀 코., 엘티디. 2개의 노크-오버로 형성된 비트 사이에 조절 가능한 간극을 갖는 횡편기 구조

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1509587A (en) * 1975-08-19 1978-05-04 Ajinomoto Kk Anti-tumour composition
FR2558372B1 (fr) * 1984-01-25 1987-08-07 Oreal Composition medicamenteuse pour le traitement de l'acne
US5008295A (en) * 1987-07-30 1991-04-16 Lion Corporation Method inhibiting the growth of cancer cells
EP0393690B1 (en) * 1989-04-21 1995-03-29 Kirin Beer Kabushiki Kaisha DNA sequences useful for the synthesis of carotenoids
FR2664164A1 (fr) * 1990-07-04 1992-01-10 Texinfine Patrinove Composition dermatologique ou cosmetique.

Also Published As

Publication number Publication date
AU5201493A (en) 1994-06-09
CN1142774C (zh) 2004-03-24
MX9307509A (es) 1997-06-28
IL103920A0 (en) 1993-04-04
DK0600544T3 (da) 2002-11-18
EP0600544A1 (en) 1994-06-08
EP0600544B1 (en) 2002-10-02
ZA938791B (en) 1994-10-03
CN1095589A (zh) 1994-11-30
ATE225168T1 (de) 2002-10-15
US5827900A (en) 1998-10-27
CA2109750A1 (en) 1994-05-31
IL103920A (en) 2000-07-26
DE69332350T2 (de) 2003-06-18
JPH06227970A (ja) 1994-08-16
KR100301682B1 (ko) 2001-10-22
DE69332350D1 (de) 2002-11-07
AU679467B2 (en) 1997-07-03
KR940011010A (ko) 1994-06-20

Similar Documents

Publication Publication Date Title
ATE370730T1 (de) Pharmazeutische zubereitungen, die chelatbildner/sequestriermittel enthalten und deren dermatologische verwendung
ES2176421T3 (es) Composicion topica gelificada estable que contiene un electrolito, un agente activo y etil hidroxietilcelulosa.
ES2138271T3 (es) Compuestos de 6-dimetil-amino-metil-1-fenil-ciclohexano como principio activo farmaceutico.
MX9307509A (es) Metodo y preparacion farmaceutica para reducir la actividad de las celulas.
MX9306735A (es) Nuevos agentes antimicrobianos polimericos y su uso en composiones farmaceuticas.
ES2123323T3 (es) Asociacion de un compuesto con actividad antimicrobiana (por ejemplo lipoaminoacido n,n-octanoilglicina) y de un monoalquileter de glicerol y su uso como agente antimicrobiano.
UA19303A (uk) Спосіб одержаhhя похідhих 2-аhіліhопіримідиhу
SV1994000071A (es) Procedimiento de una etapa para la fabricacion de derivados de acido 3-quinoloncarboxilico, ref. le a 29 572-sv.
ES2089687T3 (es) 4-fenil-piridonas y 4-fenil-2-alcoxipiridinas sustituidas como inhibidores de la hmg-coa-reductasa.
ES2043671T3 (es) Una composicion para aplicacion a un sitio vegetal.
DK0969843T3 (da) Antitussive formuleringer indeholdende theobromin
NO954506D0 (no) Hellbare, topiske formuleringer inneholdende polymert materiale, glycoler og glycerider
ES2137125B1 (es) La utilizacion de la sal de zinc del acido glicirretico en preparados contra el acne y las composiciones que contienen dicha sal.
ES2089899T5 (es) Mezclas microbicidas que contienen procloraz y ciprodinil.
ES2078378T3 (es) Composiciones que tienen actividad herbicida conteniendo n-alquil-amidas como ingrediente activo.
MX9304456A (es) Composiciones pesticidas estables en almacenamiento que comprenden azadiractina y epoxido.
ES2118726T3 (es) Factor de crecimiento epidermal como medicamento para la restauracion de neuronas de la substantia nigra en el tratamiento de trastornos neurodegenerativos.
DK0613368T3 (da) Hudregenererende kosmetisk sammensætning
IT8021550A0 (it) Derivati adenosinici ad attivita'antinfiammatoria ed analgesica e composizioni terapeutiche che licontengono come principio attivo.
AU749923C (en) The use of combinations of active agents consisting of antimicrobially active substances and plant extracts containing terpene in veterinary medicine
AR022017A1 (es) Un agente para tratar el trastorno de la funcion de las celulas visuales. el metodo de tratamiento y el uso de dicho agente para la produccion de unacomposicion farmaceutica
ES2189206T3 (es) Beta-alcoxiacrilatos contra la malaria.
ES2191426T3 (es) Composiciones estables que comprenden levosimendano y acido alginico.
AR024497A1 (es) Composiciones cosmeticas para el cuidado de la piel que contienen alcohol cumico
ES2059756T3 (es) Composiciones farmaceuticas que contienen primicina.